<DOC>
	<DOCNO>NCT00172380</DOCNO>
	<brief_summary>To assess overall response rate docetaxel plus CDDP neoadjuvant chemotherapy prior surgery , follow adjuvant docetaxel plus CDDP chemonaive patient NSCLC Stage IIIa IIIb .</brief_summary>
	<brief_title>Phase II Study Docetaxel Plus CDDP NSCLC Stage III</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC , respectable NSCLC stage IIIa T12 N2 unresectable stage IIIb 2.KPS &gt; 70 % 3.Hb &gt; 10g/dl , ANC &gt; 2.0x109/L , Plt. &gt; 100x109/L4.Tbil. &lt; 1xULN , creatinine &lt; 1xULN , creatinine clearance &gt; 60 ml/min , GPT/GOT &lt; 2.5xULN , ALP &lt; 5xULN 1.Brain meta.2..Prior surgery , R/T , C/t immunotherapy NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>